Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Memorial Sloan Kettering

Neither a doctor nor a teaching hospital

Research payments

$23,407,472

407 payments

Through program year 2025, Memorial Sloan Kettering is reported as receiving $23,407,472 in research payments, across 407 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,903,230 32
2024 Research $1,954,877 23
2023 Research $4,684,095 122
2022 Research $6,177,368 94
2021 Research $4,975,719 43
2020 Research $1,743,914 60
2019 Research $968,270 33

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $8,216,754 52 payments
  2. Astellas US Technologies $4,999,996 38 payments
  3. Pfizer Inc. $2,825,432 73 payments
  4. Celgene Corporation $2,422,505 2 payments
  5. Genentech, Inc. $2,040,695 58 payments
  6. TESARO, Inc. $483,953 11 payments
  7. Syndax Pharmaceuticals, Inc. $459,721 7 payments
  8. Array BioPharma Inc. $418,033 15 payments
  9. Immunocore Limited $367,358 74 payments
  10. Regeneron Pharmaceuticals, Inc. $342,104 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib POLAR for Individuals with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency $5,356,475 2 payments
  2. Enfortumab Vedotin and Pembrolizumab Prior to Cystectomy for Locally Advanced Urothelial Cancer $3,893,250 29 payments
  3. Phase II Multicenter Trial of anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for Multiple Myeloma Patients with Sub-Optimal Response After Autologous Hematopoietic Cell Transplantation and Maintenance Lenalidomide $2,422,505 2 payments
  4. A Phase II Study of Pembrolizumab and Ablative Radiotherapy with or without Olaparib in Metastatic Triple-Negative Breast CancerS PROMIS $1,055,554 2 payments
  5. PH I Dose Escalation W GDC 0077 in Breast Cancer $993,229 27 payments
  6. A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib POLAR for Individuals with Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency $870,610 3 payments
  7. Phase II Trial of Enfortumab Vedotin in Recurrent and/or Metastatic Adenoid Cystic Carcinoma $685,396 5 payments
  8. Encorafenibbinimetinib Master Protocol An Openlabel Continuation Study for Participants Continuing From Encorafenibbinimetinib Clinical Studies $617,648 22 payments
  9. A Phase Ib Study of the Combination of Cd47 Blockade With Sirpalpha FC Fusion Proteins Tti621 Or Tti622 and Daratumumab Hyaluronidasefihj for Patients With Relapsed Or Refractory Multiple Myeloma $566,277 2 payments
  10. PH I Ib II of Tigit Apdl 1 $522,357 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record